SCHEMBL4938178

SCHEMBL4938178

CCOC(=O)CCCN[C@@H](CC)C(=O)OC

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.46
KMT2A Q03164 2/20 0.43
POLB P06746 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.41
GAA P10253 2/20 0.41
MGAM O43451 1/20 0.41
SI P14410 1/20 0.41
MGAM2 Q2M2H8 1/20 0.41
CYP3A4 P08684 2/20 0.40
CYP2C19 P33261 2/20 0.40
CYP2D6 P10635 1/20 0.40
PDE5A O76074 1/20 0.40
TOP2A P11388 1/20 0.39
NR1I2 O75469 1/20 0.38
PGR P06401 1/20 0.38
ADORA3 P0DMS8 1/20 0.38
PTGS2 P35354 1/20 0.38
PDE4D Q08499 1/20 0.38
ALDH1A1 P00352 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL28728545 0.98 CYP1A2 (0.44) CYP1A2KMT2APOLBL3MBTL1GAA
Hydrochloric Acid SCHEMBL28728546 0.98 CYP1A2 (0.44) CYP1A2KMT2APOLBL3MBTL1GAA
SCHEMBL4938195 0.90 TSHR (0.48) L3MBTL1CYP3A4ALDH1A1
SCHEMBL4940399 0.90 TSHR (0.48) L3MBTL1CYP3A4ALDH1A1
SCHEMBL8501849 0.90 TSHR (0.48) L3MBTL1CYP3A4ALDH1A1
SCHEMBL13788520 0.87 CYP1A2 (0.46) CYP1A2KMT2APOLBL3MBTL1GAA
SCHEMBL4944206 0.85 CYP1A2 (0.49) CYP1A2KMT2APOLBL3MBTL1GAA
SCHEMBL7197714 0.85 CYP1A2 (0.44) CYP1A2KMT2APOLBL3MBTL1GAA
SCHEMBL5037810 0.85 CYP1A2 (0.49) CYP1A2KMT2APOLBL3MBTL1GAA
SCHEMBL4940078 0.85 CYP1A2 (0.49) CYP1A2KMT2APOLBL3MBTL1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338621-B2 Process for the preparation of 2-oxo-1-pyrrolidine derivatives UCB S.A. (BE) 2012-12-25 US disclosed
US-8338621-B2 Process for the preparation of 2-oxo-1-pyrrolidine derivatives UCB S.A. (BE) 2012-12-25 US disclosed
US-8338621-B2 Process for the preparation of 2-oxo-1-pyrrolidine derivatives UCB S.A. (BE) 2012-12-25 US disclosed
US-7563912-B2 Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of Levetiracetam and analogues UCB PHARMA, S.A. (BE) 2009-07-21 US disclosed
US-7563912-B2 Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of Levetiracetam and analogues UCB PHARMA, S.A. (BE) 2009-07-21 US disclosed
EP-1419144-B1 OXOPYRROLIDINE COMPOUNDS, PREPARATION OF SAID COMPOUNDS AND THEIR USE IN THE MANUFACTURING OF LEVETIRACETAM AND ANALOGUES UCB PHARMA SA (BE) 2008-10-08 EP disclosed
US-20080009638-A1 PROCESS FOR THE PREPARATION OF 2-OXO-1-PYRROLIDINE DERIVATIVES UCB S.A. (BE) 2008-01-10 US disclosed
US-20080009638-A1 PROCESS FOR THE PREPARATION OF 2-OXO-1-PYRROLIDINE DERIVATIVES UCB S.A. (BE) 2008-01-10 US disclosed
US-20080009638-A1 PROCESS FOR THE PREPARATION OF 2-OXO-1-PYRROLIDINE DERIVATIVES UCB S.A. (BE) 2008-01-10 US disclosed
EP-1806339-A1 Process for the preparation of 2-oxo-1-pyrrolidine derivatives UCB, S.A. (BE) 2007-07-11 EP disclosed
EP-1806339-A1 Process for the preparation of 2-oxo-1-pyrrolidine derivatives UCB, S.A. (BE) 2007-07-11 EP disclosed
US-20070142647-A1 Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of levetiracetam and analogues ATES CELAL 2007-06-21 US disclosed
US-20070142647-A1 Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of levetiracetam and analogues ATES CELAL 2007-06-21 US disclosed
WO-2003014080-A2 OXOPYRROLIDINE COMPOUNDS, PREPARATION OF SAID COMPOUNDS AND THEIR USE IN THE MANUFACTURING OF LEVETIRACETAM AND ANALOGUES UCB, S.A. (BE) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080009638-A1 PROCESS FOR THE PREPARATION OF 2-OXO-1-PYRROLIDINE DERIVATIVES CYP2F1, CYP3A5, SULT1E1 CYP1A2 30/4885KMT2A 490/4885POLB 860/4885
US-20070142647-A1 Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of levetiracetam and analogues CYP2D6, OTC, CYP2B6 CYP1A2 16/4885KMT2A 133/4885POLB 1679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.